Ratings Asahi Kasei Corporation

Equities

3407

JP3111200006

Delayed Japan Exchange Other stock markets 09:58:07 2024-04-23 pm EDT			5-day change	1st Jan Change
1,100 ^JPY	+0.05%		+0.14%	+5.77%

Apr. 22	Cyto-Facto Inc. announced that it has received ¥1.18 billion in funding from a group of investors	CI
Apr. 19	Aidiot,inc. announced that it has received funding from Mizuho Capital Co., Ltd., Asahi Kasei Corporation	CI

Summary

The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

With regards to fundamentals, the enterprise value to sales ratio is at 0.79 for the current period. Therefore, the company is undervalued.
The company appears to be poorly valued given its net asset value.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company sustains low margins.
For the last few months, analysts have been revising downwards their earnings forecast.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Diversified Chemicals

	1st Jan change	Capi.	ESG Refinitiv
ASAHI KASEI CORPORATION	+5.77%	9.93B	A-
BASF SE	+4.72%	48.55B	A-
DUPONT DE NEMOURS, INC.	-4.06%	30.9B	C
PIDILITE INDUSTRIES LIMITED	+7.34%	17.68B	B
BRENNTAG SE	-9.28%	11.46B	B
EASTMAN CHEMICAL COMPANY	+7.77%	11.41B	A-
SYENSQO SA/NV	-7.36%	9.77B	-
SRF LIMITED	+5.52%	9.12B	C-
MITSUBISHI CHEMICAL GROUP CORPORATION	+4.87%	8.42B	B
SAHARA INTERNATIONAL PETROCHEMICAL COMPANY	-5.29%	6.19B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes